RNA interference

PASADENA, Calif. — September 15, 2026 Arrowhead Pharmaceuticals, Inc. announced interim topline clinical data from the Phase 1/2a ARODIMER-PA-1001...

SOUTH SAN FRANCISCO and SAN DIEGO — September 8, 2026 Moonwalk Biosciences announced the closing of an oversubscribed $70...

Cambridge, Mass. – August 30, 2026 Alnylam Pharmaceuticals announced new clinical data at the European Society of Cardiology (ESC)...

Pasadena, Calif. – August 30, 2026 Arrowhead Pharmaceuticals presented detailed Phase 3 SHASTA-3 and SHASTA-4 data showing that plozasiran...

CAMBRIDGE, Massachusetts, USA & PALO ALTO, California, USA, June 3, 2026 Alnylam Pharmaceuticals and Inceptive Nucleics have announced a...

Pasadena, California | April 24, 2026 Arrowhead Pharmaceuticals has achieved a major regulatory milestone as the Committee for Medicinal...

South San Francisco, California — March 5, 2026 Tenaya Therapeutics and Alnylam Pharmaceuticals have announced a major research collaboration...

King of Prussia, Pennsylvania | December 23, 2025 — Phio Pharmaceuticals Corp. announced a significant advancement in its drug...